Summary European clinical trials of zonisamide as adjunctive therapy for refractory partial seizures included a 12-week double-blind, placebo-controlled study and a 15-month open-label extension study. In the double-blind study, patients (n = 144) were randomized to placebo or zonisamide (400 mg QD) after baseline evaluation. Patients completing the double-bind study (n = 115) continued on open-label zonisamide for up to 18 months. Median percent reduction in partial seizures from baseline was significantly greater in zonisamide-treated patients compared to those receiving placebo (31.6% versus 3.3%, respectively; P = 0.008). Additionally, more zonisamidetreated patients achieved ≥50% reduction in seizure frequency relative to baseline than did placebo patients (30.4% versus 14.7%, respectively; P = 0.03). The extension study showed that zonisamide efficacy was maintained or improved over time. Patient and physician assessments favored zonisamide over placebo in terms of patient improvement with treatment. Median zonisamide maintenance dosage was 400 mg/day, and the average therapeutic blood level was 16.9 g/mL. Both studies showed that zonisamide was well tolerated; adverse events were generally mild to moderate and most frequently included fatigue, dizziness, somnolence, and anorexia.
Introduction
Zonisamide (Zonegran ® ), a sulfonamide analogue with broad-spectrum anticonvulsant activity, 1 has been prescribed in Japan and Korea for 15 and 12 years, respectively, and recently received regulatory approval in the United States and Europe opment is continuing under the sponsorship of Eisai Inc.
The European trial was conducted in two phases: it began with a double-blind, placebo-controlled study, and was followed by an open-label extension in which all patients received long-term zonisamide treatment. The primary objective of these studies was to evaluate the efficacy and safety of zonisamide as an adjunctive therapy for patients with refractory partial seizures. Another objective was to determine the dose and plasma levels of zonisamide associated with significant seizure reduction. 
Method
Placebo-controlled study A total of 144 patients at 10 sites were randomized to treatment with zonisamide or placebo (Table 1) .
Patients were included in the study if they were between 18 and 59 years of age, had a history of refractory partial seizures (at least four seizures per month in the previous 4 months), and were being treated with one or two antiepilepsy drugs (AEDs), but not more than two of the following: phenytoin, carbamazepine, sodium valproate, phenobarbital, or primidone. In addition, patients had to be capable of counting the number of seizures that they experienced, because their record of seizure activity was an important component of the study data. Patients who had progressive central nervous system disease, more than eight generalized tonic-clonic seizures while awake during the 4 months prior to the study, significant mental retardation, a history of drug or alcohol abuse, or abnormal laboratory values unrelated to AED therapy were not eligible for participation in the study. Results from 9 of the 10 centers have been published previously by Schmidt et al. 2 Baseline seizure data were recorded daily for the first 8 weeks of the study (Table 1 and Fig. 1 ). During this baseline period, patients continued to take previously prescribed AEDs. Patients who recorded at least 30 seizures during this baseline period proceeded directly to the treatment introduction phase; those who had fewer than 30 seizures during this time continued recording seizure activity for an additional 4 weeks before the treatment introduction phase was begun.
Following the baseline period, each patient was randomly assigned to receive zonisamide or placebo, in addition to their other AEDs, for 12 weeks (Fig. 1 ). Treatment was introduced over a titration period of 4 weeks, during which zonisamide dosing began at 100 mg/day for the first week, increased to 200 mg/day for the second week, and to 400 mg/day for the third and fourth weeks. Zonisamide was administered orally as capsules containing 100 mg of the drug; placebo also was titrated from one to four capsules per day. After titration, zonisamide doses were measured using a high-performance liquid chromatography (HPLC) method, and adjusted by a nonblinded observer to achieve a blood level of 20-30 g/mL, a range that had been shown in previous studies to be a level associated with high efficacy. 3, 4 The nonblinded observer also ensured that zonisamide doses did not exceed 20 mg/kg per day and that zonisamide plasma levels did not exceed 40 g/mL. Random adjustments were made in the number of placebo capsules to maintain the study blind. All patients continued at the adjusted dosage levels for 8 weeks beyond the titration period. Postrandomization seizure data were not obtainable from seven patients; thus, data analyzed were for an intent-to-treat population consisting of 137 patients.
Efficacy measures included median change from baseline in seizure frequency, and the percentage of treatment responders over the full-dose, 8-week treatment period. A treatment responder was defined as any patient who achieved a ≥50% reduction in seizure frequency relative to baseline. Additional efficacy measures included physician and patient global assessments, made either at the completion of the 12-week double-blind treatment period, or at the time of withdrawal from the study. Each patient and physician independently rated the changes in the patient's condition with treatment as markedly improved, slightly improved, unchanged, or worse. Safety was assessed based on the frequency and severity of adverse events, as well as on results from laboratory tests (hematology, chemistry, and urinalysis) and electroencephalogram (EEG) evaluations.
Open-label study
Patients who completed the double-blind study were eligible to enroll in an open-label extension study to examine the long-term safety and efficacy of zonisamide. A total of 115 patients from 10 centers entered the open-label study. Fifty-three of these patients had received zonisamide during the double-blind study and continued at the same dose throughout the open-label study for a total mean duration of therapy of 445 days (median dose of 500 mg/day). The 62 patients who had received Figure 2 Comparison of zonisamide (black bars) and placebo (gray bars) treatment on efficacy endpoints for patients in the double-blind study. Efficacy endpoints were the median percentage seizure reduction from baseline (a), and the percentage of patients with ≥50% seizure reduction from baseline (b), for all partial seizures, complex partial seizures, and all seizures. Statistical comparisons were made using a two-way analysis of variance (ANOVA) test using treatment and site as factors. placebo began taking zonisamide at doses titrated over a 4-week period to 400-600 mg/day; they remained at this dose for a total mean duration of 321 days. Zonisamide doses could be adjusted based on investigators' clinical judgment, provided that daily dosage did not exceed 20 mg/kg per day or an amount producing zonisamide plasma levels of 40 g/mL.
For the open-label study, efficacy measures were percent reduction in seizure frequency relative to baseline and response rate. Safety was assessed in terms of the frequency and severity of adverse events.
Results

Placebo-controlled study: efficacy findings
As shown in Fig. 2 , in the placebo-controlled study, zonisamide treatment produced a significant reduction in seizure activity for all partial seizures, complex partial seizures, and all seizures (partial and generalized). Zonisamide treatment also produced a significant increase in the percentage of patients who were considered responders for all partial seizures and all seizures. A strong trend toward an increased response rate for complex partial seizures (P = 0.055) was also observed in patients treated with zonisamide. Furthermore, both physician and patient global assessments indicated a significantly greater level of improvement than was seen with placebo ( Fig. 3) . Although the median dose of zonisamide given to responders was the same as nonresponders (400 mg/day), weight-adjusted doses were somewhat lower among nonresponders ( Table 2 ). Among responders, 16 patients received between 400 and 600 mg/day, and the remaining patient received a dose of 200 mg/day (data not shown). Median plasma levels of zonisamide were 16.9 and 13.0 g/mL for responders and nonresponders, respectively. Therapeutic dosage and plasma levels for zonisamide observed in this study are within the ranges of those reported elsewhere. 1, [3] [4] [5] Other AEDs taken by patients in this study were carbamazepine, phenytoin, sodium valproate, primidone, and phenobarbital. Blood levels of all concomitant AEDs were nearly identical before and after zonisamide treatment (Fig. 4) . 2 These results suggest that zonisamide does not affect the metabolism of these concomitant AEDs, and that the efficacy of zonisamide is not secondary to changes in the levels of concomitant AEDs.
Safety findings
Adverse events that occurred with the use of zonisamide were considered mild or moderate in severity, and are similar to those encountered with other AEDs. Overall, 45 (62%) patients receiving zonisamide, and 22 (31%) patients given the placebo, reported one or more treatment-emergent adverse event(s). The most frequent adverse events (those occurring in ≥10% of patients) were fatigue, dizziness, somnolence, anorexia, ataxia, and trouble concentrating ( Table 3 ). The frequency of dizziness, anorexia, ataxia, and trouble concentrating were significantly increased among patients treated with zonisamide relative to those treated with placebo suggesting that these adverse events were attributable to the addition of zonisamide treatment to other AEDs. No clear relationship was observed between zonisamide plasma levels and frequency or type of adverse events. Five of the patients treated with zonisamide, and one patient treated with placebo, withdrew from the double-blind study because of adverse events. Those events experienced by the zonisamide-treated patients were nervousness, fatigue, drowsiness, difficulty concentrating, memory problems, and headache; the patient who received placebo reported fatigue, difficulty concentrating, apathy, and hair loss.
Laboratory tests (hematology, chemistry, urinalysis) showed no changes of clinical consequence. EEG evaluations showed changes expected of patients with refractory seizures. Seventeen patients treated with zonisamide, and 14 patients treated with placebo, showed significant changes in labora- 
Results
Open-label study: efficacy findings
Of the 115 patients who began the open-label study, 32 (28%) patients were treated with zonisamide for more than 15 months, and 52 (45%) patients were treated for at least 12 months. Because of missing baseline data for four patients, the efficacy analysis included 111 patients. The median percent reduction from baseline in seizure frequency was 45.4% for all partial seizures and 47.0% for complex partial seizures. Between 33 and 55% of all patients were responders (experiencing a ≥50% reduction in seizure frequency) for all seizure categories, depending on the time interval assessed (months 4-6, 7-9, 10-12, 13-15, ≥15). In addition, comparison of response rates from the placebo-controlled study with those from the extension study shows that the efficacy of zonisamide was maintained over time.
Safety findings
The most frequent adverse events observed with long-term zonisamide treatment were fatigue (23% in the original zonisamide group versus 16% in the previous placebo group), somnolence (9% versus 21%), trouble concentrating (11% versus 16%), anorexia (9% versus 14%), and depression (4% versus 9%). All adverse events were characterized as mild or moderate, and only 18.3% of all adverse events were considered by study investigators to be related to zonisamide treatment. Nineteen patients (16.5%) withdrew from the study as a result of adverse events. Two patients experienced serious or potentially serious adverse events during this study, including carcinoma and renal calculi. A third patient died. The cause of death was unrelated to the study drug.
Discussions and conclusions
These studies demonstrate that zonisamide is a safe and effective adjunctive treatment for epilepsy. Zonisamide was well tolerated during short-and long-term treatment. In addition, the lack of any effect of zonisamide on concomitant AED levels favors its use in polytherapy. These conclusions are in agreement with those from clinical trials conducted with zonisamide in Japan and the United States, and from extensive postmarketing experience in Japan and Korea.
